Listening to the interview it sounded like the meb001 fda fast track was actually just a punt by the company to get things sped up. For how much the sp is being punished it’s not really justified. Cheap shares at the moment with nothing really fundamentally changed. The compass deal and the consumer app next year are what interest me most at the moment. fda will be icing on the cake.
Ann: FDA Strategy and Regulatory Update, page-490
-
- There are more pages in this discussion • 203 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
